KALV
NASDAQ · Biotechnology
Kalvista Pharmaceuticals Inc
$27.00
+0.01 (+0.04%)
Open$26.98
Previous Close$26.99
Day High$27.00
Day Low$26.98
52W High$27.00
52W Low$10.41
Volume—
Avg Volume2.31M
Market Cap1.44B
P/E Ratio—
EPS$-1.58
SectorBiotechnology
Analyst Ratings
Hold
13 analysts
Price Target
+139.9% upside
Current
$27.00
$27.00
Target
$64.76
$64.76
$35.35
$64.76 avg
$75.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 48.50M | 272.43M | 275.70M |
| Net Income | -108,244,051 | -77,974,346 | -85,417,882 |
| Profit Margin | -223.2% | -28.6% | -31.0% |
| EBITDA | -109,772,064 | -125,574,606 | -125,457,307 |
| Free Cash Flow | — | -59,177,907 | -68,220,346 |
| Rev Growth | — | +3.3% | +15.2% |
| Debt/Equity | 1.11 | 0.07 | 0.09 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |